Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 1

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 3
Chunk 1
---
 these losses to increase substantially if and as we:

  continue our research and development efforts and submit applications seeking marketing authorizations in the United States or authorizations or certifications outside the United States for our...  

  conduct and expand the scope of our preclinical studies and clinical trials for our Alpha DaRT technology;  

  continue to develop manufacturing facilities for our Alpha DaRT technology;  

  seek to identify additional potential indications for our Alpha DaRT technology;  

  acquire or in-license other products or product candidates or technologies;  

  add operational, financial and management information systems and personnel, including personnel to help us comply with our obligations as a public company;  

  hire and retain additional personnel, such as clinical, quality control, scientific, commercial and administrative personnel, including personnel to support the development and potential commer...  

  seek marketing authorizations or certifications for our Alpha DaRT technology or any other product candidates that successfully complete clinical trials;  

  establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities, whether alone or with third parties, to commercialize our Alpha DaRT technology or other pr...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  expand, maintain and protect our intellectual property portfolio; and  

  continue to operate as a public company.  

Because of the numerous risks
and uncertainties associated with the medical device industry, we are unable to accurately predict the timing or amount of increased expenses
we will incur or when, if ever, we will be able to achieve profitability. Even if we succeed in commercializing our Alpha DaRT technology
in one indication, we will continue to incur substantial research and development and other expenditures to develop, seek marketing authorizations
or certifications for, and potentially market our Alpha DaRT technology in other indications. We may encounter unforeseen expenses, difficulties,
complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend,
in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses
have had and will continue to have an adverse effect on our shareholders’ equity and working capital.

In addition, we regularly
maintain cash, cash equivalents and bank deposits at financial institutions in the United States, Israel and other multi-national institutions.
Our funds at these institutions exceed insured limits and some are not insured at all. In the event of failure of any financial